Double-Blind, Placebo-Controlled Trial of Risperidone Plus Amantadine in Children With Autism: A 10-Week Randomized Study
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study aimed to investigate the effect of adding amantadine to risperidone for treatment of autism. METHODS: Forty outpatients aged 4 to12 years, who were diagnosed with autism spectrum disorders based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria, were assigned to this double-blind clinical trial. The subjects were divided randomly into 2 groups. One group received risperidone plus amantadine, and the other group received risperidone plus placebo. The dose of risperidone was titrated between 1 and 2.0 mg/d, and the dose of amantadine was 100 or 150 mg/d for patients less than 30 kg or more than 30 kg, respectively. The patients were assessed using the Aberrant Behavioral Checklist-Community (ABC-C) and adverse effects checklist as well as clinical global impression-improvement (CGI-I) at2 checkpoints of 5-week intervals after the baseline. Informed consentwas obtained from the parents of each participant. RESULTS: Among ABC-C subscales, Hyperactivity and Irritability showed significantly greater reduction in the amantadine group than the placebo group. There was no significant difference in adverse effects between the 2 groups. The CGI-I scores show significant improvement in the amantadine group compared to the placebo group. CONCLUSIONS: The present study suggests that amantadine may be a potential adjunctive treatment strategy for autism and it was generally well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Immune involvement in schizophrenia and autism: Etiology, pathology and animal models
Patterson, P. H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.12.016 · Cited by 766 · cited 2×
“Lower cholinergic transmission has been reported in the brains of patients with autistic disorders.(31) Amantadine with its anticholinergic properties might exacerbate this pathology.”
BackgroundPardo, C. A., & Eberhart, C. G. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00102.x · Cited by 514
A Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders
McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., & Veenstra-VanderWeele, J. (2011) · Pediatrics · doi:10.1542/peds.2011-0427 · Cited by 356 · cited 1×
“As its secondary effects, risperidone has some beneficial effects on the core symptoms of autism.(21) As described previously, amantadine can target 2 separate domains in the pathogenesis of autism (both the glutamate system and immunologic dysregulation).”
BackgroundNeurochemical correlates of autistic disorder: a review of the literature
Lam, K. S. L., Aman, M. G., & Arnold, L. E. (2006) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2005.03.003 · Cited by 318 · cited 1×
“Amantadine with its anticholinergic properties might exacerbate this pathology.(32) Besides, overactivity of dopaminergic system is well documented in autism.”
Background
Cited by
Aggression in autism spectrum disorder: presentation and treatment options
Fitzpatrick, S., Srivorakiat, L., Wink, L., Pedapati, E., & Erickson, C. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s84585 · Cited by 271
An update on pharmacotherapy for autism spectrum disorder in children and adolescents
Ji, N. Y., & Findling, R. L. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000132 · Cited by 217
Complementary and Alternative Therapies for Autism Spectrum Disorder
Brondino, N., Fusar-Poli, L., Rocchetti, M., Provenzani, U., Barale, F., & Politi, P. (2015) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2015/258589 · Cited by 116
Frye, R. E., & Rossignol, D. A. (2016) · Clinical Medicine Insights Pediatrics · doi:10.4137/cmped.s38337 · Cited by 96
Masi, A., Lampit, A., Glozier, N., Hickie, I. B., & Guastella, A. J. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.143 · Cited by 78
Metadata
- Authors
- Mohammadi, M.-R., Yadegari, N., Hassanzadeh, E., Farokhnia, M., Yekehtaz, H., Mirshafiee, O., & Akhondzadeh, S.
- Venue
- Clinical Neuropharmacology
- Published
- 2013-11
- Volume
- 36
- Issue
- 6
- Pages
- 179-184
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W2084609003
- Cited by
- 61
- References
- 5
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Double-Blind, Placebo-Controlled Trial of Risperidone Plus Amantadine in Children With Autism: A 10-Week Randomized Study. https://app.cochat.ai/papers/10.1097/wnf.0b013e3182a9339d
- The paper
- Mohammadi, M.-R., Yadegari, N., Hassanzadeh, E., Farokhnia, M., Yekehtaz, H., Mirshafiee, O., & Akhondzadeh, S. (2013). Double-Blind, Placebo-Controlled Trial of Risperidone Plus Amantadine in Children With Autism: A 10-Week Randomized Study. Clinical Neuropharmacology. https://doi.org/10.1097/wnf.0b013e3182a9339d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.